Piramal Pharma - PPLPHARMA, 543635 corporate action history

Piramal Pharma Ltd.

NSE: PPLPHARMA | BSE: 543635

Falling Comet

Download real time

134.36 -3.99 (-2.88%)

New 52W Low today

1.8M

NSE+BSE Volume

NSE 23 Mar, 2026 12:06 PM (IST)

Piramal Pharma Bonus history

Piramal Pharma has not announced any bonus since Jan 1, 2000.

See all forthcoming Bonus and Splits

Piramal Pharma Split history

Piramal Pharma has not split the face value of the share since Jan 1, 2000.

See all forthcoming Bonus and Splits

Dividend history for Piramal Pharma

Piramal Pharma has declared 2 dividends since July 12, 2024.

In the past 12 months, Piramal Pharma has declared an equity dividend amounting to ₹0.14 per share.

At the current share price of ₹134.3600, Piramal Pharma's dividend yield is 0.10%.

Ex-Date	Dividend Amount	Dividend Type	Record Date	Instrument Type
16 Jul 2025	0.14	FINAL	16 Jul 2025	Equity Share
12 Jul 2024	0.11	FINAL	12 Jul 2024	Equity Share

See all forthcoming dividends Check out stocks with top dividend.

Board Meetings - Piramal Pharma

The latest board meeting for Piramal Pharma took place on 28 Jan 2026, for the purpose of Quarterly Results

Ex-Date	Purpose	Notes
28 Jan 2026	Quarterly Results	-
05 Nov 2025	Quarterly Results	-
28 Jul 2025	Quarterly Results	-
14 May 2025	Audited Results & Final Dividend	-
28 Jan 2025	Quarterly Results	-
23 Oct 2024	Quarterly Results	-
26 Jul 2024	Quarterly Results	-
10 May 2024	Audited Results & Final Dividend	-
30 Jan 2024	Quarterly Results	-
27 Oct 2023	Quarterly Results	-

See all Board Meetings for Piramal Pharma

Rights history for Piramal Pharma

Piramal Pharma issued rights 1 time since Aug. 2, 2023. Piramal Pharma had last issued Rights shares of ₹10.0/- in the ratio of 5.0:46.0 @ premium of ₹71.0/- on Aug. 2, 2023.

Ex-Date	Ratio	Face Value	Premium	Record Date
02 Aug 2023	5.0:46.0	10.0	71.0	02 Aug 2023

See all Rights History for Piramal Pharma

VOTE: Is Piramal Pharma Ltd. worth buying?

404 Votes:

Buy 82.92%

Sell 10.89%

Hold 6.19%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >